Real-world Study on Factors Associated with Replase in Patients with Rheumatoid Arthritis in Clinical Remission Period

YAO Chuanhui; JIANG Quan; XIA Congmin; LIU Weixiang; PENG Qiuwei; ZHANG Fuyuan; SONG Mengge; SHANG Biyue; GONG Xun; TANG Xiaopo

doi:10.13288/j.11-2166/r.2023.13.010

您当前的位置：

首页 >

文章列表页 >

Real-world Study on Factors Associated with Replase in Patients with Rheumatoid Arthritis in Clinical Remission Period

更新时间：2023-06-30

- Real-world Study on Factors Associated with Replase in Patients with Rheumatoid Arthritis in Clinical Remission Period
- Journal of Traditional Chinese Medicine Vol. 64, Issue 13, Pages: 1343-1350(2023)
- 作者机构：
  
  中国中医科学院广安门医院，北京市西城区北线阁5号，100053
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2023.13.010
  CLC：
- Received：27 February 2023，
  
  Revised：2023-04-27，
  
  Published：02 July 2023
- 稿件说明：
移动端阅览
姚传辉,姜泉,夏聪敏等.类风湿关节炎临床缓解期患者复发相关因素的真实世界研究[J].中医杂志,2023,64(13):1343-1350.

YAO Chuanhui,JIANG Quan,XIA Congmin,et al.Real-world Study on Factors Associated with Replase in Patients with Rheumatoid Arthritis in Clinical Remission Period[J].Journal of Traditional Chinese Medicine,2023,64(13):1343-1350.
姚传辉,姜泉,夏聪敏等.类风湿关节炎临床缓解期患者复发相关因素的真实世界研究[J].中医杂志,2023,64(13):1343-1350. DOI： 10.13288/j.11-2166/r.2023.13.010.

YAO Chuanhui,JIANG Quan,XIA Congmin,et al.Real-world Study on Factors Associated with Replase in Patients with Rheumatoid Arthritis in Clinical Remission Period[J].Journal of Traditional Chinese Medicine,2023,64(13):1343-1350. DOI： 10.13288/j.11-2166/r.2023.13.010.

摘要

目的

基于真实世界临床数据探讨影响类风湿关节炎（RA）临床缓解期患者疾病复发的相关因素。

方法

纳入2019年10月1日至2022年10月1日中国中医风湿病注册研究信息平台（CERTAIN）中达到临床缓解［基于血沉的28个关节疾病活动度（DAS28-ESR）评分≤2.6分］标准并接受规律随访的RA患者。收集患者人口学信息、相关临床资料及实验室检查结果。所有患者至少3个月进行1次随访，持续1年。将DAS28-ESR＞3.2分判定为复发，根据随访1年内是否复发分为持续缓解组和复发组。统计两组患者用药情况，将用药方案总体分为中药、西药、中药+西药三类。采用Cox回归分析评估RA临床缓解期患者1年内复发的影响因素。采用Kaplan-Meier分析不同用药方案（中药组、西药组、中药+西药组）患者复发情况。

结果

共纳入630例RA临床缓解期患者，其中持续缓解组284例（45.08%），复发组346例（54.92%）。多因素Cox回归分析结果显示，病程≥5年、晨僵、乏力、关节肿胀是RA临床缓解期复发的危险因素（

＜0.05或

＜0.01）；中药、中药+西药治疗是RA临床缓解期复发的保护因素（

＜0.01）。Kaplan-Meier曲线分析显示，西药组、中药组、中药+西药组患者1年内复发率分别为69.34%、51.85%、50.73%，中药组、中药+西药组较西药组差异有统计学意义（

＜0.01）。

结论

RA临床缓解期在1年内复发率较高，病程长、晨僵、乏力、关节肿胀是导致RA复发的重要因素，持续中药或中药联合西药治疗则有助于RA持续缓解。

Abstract

Objective

To explore the related factors associated with relapse in patients with rheumatoid arthritis （RA） during clinical remission period based on real-world data.

Methods

Patients with RA who achieved clinical remission， that is the disease activity score-28 for rheumatoid arthritis with erythrocyte sedimentation rate（DAS28-ESR）≤2.6， and received regular follow-up in the China Rheumatoid Arthritis Registry of Patients with Chinese Medicine（CERTAIN） from October 1st， 2019 to October 1st， 2022 were included in the study. Baseline demographic， clinical， and laboratory data were collected. All patients were followed up at least once every 3 months for 1 year. Relapse was defined as DAS28-ESR greater than 3.2， and therefore patients were divided into the sustained remission group and the relapse group. According to the medications of patients， there were generally three categories， which were Chinese herbal medicine （CHM）， western medicine， and the integrated medicine （CHM plus western medicine）. Cox regression analysis was used to identify factors associated with relapse in patients with remission-phase RA. The Kaplan-Meier method was used to analyze the relapse rate among patients treated with different medication regimens （CHM， western medicine and integrated medicine）.

Results

A total of 630 patients with remission-phase RA were included in this study， of whom 284 cases （45.08%） were in the sustained remission group and 346 （54.92%） were in the relapse group . Multivariate analysis showed that disease duration of ≥5 years， morning stiffness， fatigue， and joint swelling were risk factors for relapse in patients with remission-phase RA （

＜0.05 or

＜0.01）， while the use of CHM and integrated medicine were protective factors for relapse in these patients （

＜0.01）. Kaplan-Meier curve analysis showed that the relapse rates within one year were 69.34%， 51.85%， and 50.73% in the western medicine group， CHM group， and integrated medicine group， respectively， and the CHM group and integrated medicine group had significantly lower relapse rates than the western medicine group （

＜0.01）.

Conclusion

The relapse rate within 1 year is relatively high in patients with remission-phase RA， and those with longer disease duration， morning stiffness， fatigue， and joint swelling are more likely to have relapse. The use of CHN or integrated medicine may help these patients sustain remission.

关键词

Keywords

references

FRAENKEL L ， BATHON JM ， ENGLAND BR ， et al . 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis ［J］. Arthritis Care Res （Hoboken）， 2021 ， 73 （ 7 ）： 924 - 939 .

ALETAHA D ， SMOLEN JS . Diagnosis and management of rheumatoid arthritis： a review ［J］. JAMA ， 2018 ， 320 （ 13 ）： 1360 - 1372 .

SUN X ， LI R ， CAI Y ， et al . Clinical remission of rheumatoid arthritis in a multicenter real-world study in Asia-Pacific region ［J］. Lancet Reg Health West Pac ， 2021 ， 15 ： 100240 . doi： 10.1016/j.lanwpc.2021.100240 http://dx.doi.org/10.1016/j.lanwpc.2021.100240 .

EINARSSON JT ， WILLIM M ， SAXNE T ， et al . Secular trends of sustained remission in rheumatoid arthritis，a nationwide study in Sweden ［J］. Rheumatology （Oxford）， 2020 ， 59 （ 1 ）： 205 - 212 .

LILLEGRAVEN S ， PAULSHUS SUNDLISÆTER N ， AGA AB ， et al . Effect of half-dose vs stable-dose conventional synthetic disease-modifying antirheumatic drugs on disease flares in patients with rheumatoid arthritis in remission： the ARCTIC REWIND randomized clinical trial ［J］. JAMA ， 2021 ， 325 （ 17 ）： 1755 - 1764 .

EINARSSON JT ， WILLIM M ， ERNESTAM S ， et al . Prevalence of sustained remission in rheumatoid arthritis： impact of criteria sets and disease duration， a nationwide study in Sweden ［J］. Rheumatology （Oxford）， 2019 ， 58 （ 2 ）： 227 - 236 .

GONG X ， LIU WX ， TANG XP ， et al . Traditional Chinese medicine Qingre Huoxue treatment vs.the combination of methotrexate and hydroxychloroquine for active rheumatoid arthritis：a multicenter，double-blind，randomized controlled trial ［J］. Front Pharmacol ， 2021 ， 12 ： 679588 . doi： 10.3389/fphar.2021.679588 http://dx.doi.org/10.3389/fphar.2021.679588 .

ZHONG LL ， WANG R ， LAM WC ， et al . The combination of Chinese and western medicine in the management of rheumatoid arthritis： a real-world cohort study across China ［J］. Front Pharmacol ， 2022 ， 13 ： 933519 . doi： 10. 3389/fphar.2022.933519 http://dx.doi.org/10.3389/fphar.2022.933519 .

徐才钦，姚传辉，张雨樵，等 . 类风湿关节炎住院患者中西医结合医疗质量现状调查［J］. 中日友好医院学报， 2023 ， 37 （ 1 ）： 47 - 49 .

GONG X ， LIU WX ， LI D ， et al . China rheumatoid arthritis registry of patients with Chinese medicine （CERTAIN）： rationale， design， and baseline characteristics of the first 11，764 enrollees ［J］. Phytomedicine ， 2022 ， 104 ： 154236 . doi： 10.1016/j.phymed.2022.154236 http://dx.doi.org/10.1016/j.phymed.2022.154236 .

ALETAHA D ， NEOGI T ， SILMAN AJ ， et al . 2010 rheumatoid arthritis classification criteria： an American College of Rheumatology/European League Against Rheumatism collaborative initiative ［J］. Ann Rheum Dis ， 2010 ， 69 （ 9 ）： 1580 - 1588 .

中华中医药学会风湿病分会 . 类风湿关节炎病证结合诊疗指南［J］. 中医杂志， 2018 ， 59 （ 20 ）： 1794 - 1800 .

SHEEHY C ， EVANS V ， HASTHORPE H ， et al . Revising DAS28 scores for remission in rheumatoid arthritis ［J］. Clin Rheumatol ， 2014 ， 33 （ 2 ）： 269 - 272 .

REPPING-WUTS H ， UITTERHOEVE R ， VAN RIEL P ， et al . Fatigue as experienced by patients with rheumatoid arthritis （RA）： a qualitative study ［J］. Int J Nurs Stud ， 2008 ， 45 （ 7 ）： 995 - 1002 .

FELSON DT ， ANDERSON JJ ， BOERS M ， et al . The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials ［J］. Arthritis Rheum ， 1993 ， 36 （ 6 ）： 729 - 740 .

CARTER JD ， LODHI AB ， NAGDA SR ， et al . Determining rheumatologists' accuracy at assessing functional disability in rheumatoid arthritis patients using the Health Assessment Questionnaire-Disability Index ［J］. J Rheumatol ， 2007 ， 34 （ 5 ）： 958 - 963 .

RAMIREZ J ， CUERVO A ， CELIS R ， et al . Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission：a 5 year follow-up study ［J］. Rheumatology （Oxford）， 2021 ， 60 （ 2 ）： 667 - 674 .

RADNER H ， ALASTI F ， SMOLEN JS ， et al . Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients ［J］. Arthritis Res Ther ， 2015 ， 17 （ 1 ）： 203 .

PRINCE FH ， BYKERK VP ， SHADICK NA ， et al . Sustained rheumatoid arthritis remission is uncommon in clinical practice ［J］. Arthritis Res Ther ， 2012 ， 14 （ 2 ）： R68 .

SUN J ， DAI S ， ZHANG L ， et al . Investigating the safety and compliance of using csDMARDs in rheumatoid arthritis treatment through face-to-face interviews：a cross-sectional study in China ［J］. Clin Rheumatol ， 2021 ， 40 （ 5 ）： 1789 - 1798 .

SMOLEN JS ， LANDEWE RBM ， BIJLSMA J ， et al . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs：2019 update ［J］. Ann Rheum Dis ， 2020 ， 79 （ 6 ）： 685 - 699 .

SOKOLOVA MV ， HAGEN M ， BANG H ， et al . IgA anti-citrullinated protein antibodies are associated with flares during DMARD tapering in rheumatoid arthritis ［J］. Rheumatology （Oxford）， 2022 ， 61 （ 5 ）： 2124 - 2131 .

RAHEEL S ， MATTESON EL ， CROWSON CS ， et al . Improved flare and remission pattern in rheumatoid arthritis over recent decades： a population-based study ［J］. Rheumatology （Oxford）， 2017 ， 56 （ 12 ）： 2154 - 2161 .

刘蔚翔，姜泉 . 类风湿关节炎“湿、热、瘀”病机理论探析［J］. 中医杂志， 2020 ， 61 （ 24 ）： 2148 - 2153 .

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Risk Factors for Major Adverse Cadiovascular and Cerebrovascular Events in Elderly Type 2 Diabetes Mellitus and Stable Angina Pectoris： A Real-world Study

Advantages，Challenges，and Implementation Pathways of Natural Experiments in Evaluating the Efficacy of Traditional Chinese Medicine

Correlation Between Traditional Chinese Medicine Syndromes and Rheumatoid Arthritis with Atherosclerosis：A Multicenter Cross-Sectional Study

Construction and Application of a Real-World Cohort of Community-Acquired Pneumonia Based on a Multimodal Large-Scale Traditional Chinese Medicine Big Data Platform

Clinical Efficacy and Economic Evaluation of 1293 Non-Severe Adult Patients with Community-Acquired Pneumonia Treated by the Jiangsu Traditional Chinese Medicine Diagnosis and Treatment Protocol for Dominant Diseases：A Multicenter，Retrospective Real-World Cohort Study

Related Author

Leilei LI

Yu FU

Ruixia ZHAO

Haibin YU

Mingyi SHAO

Shuxun YAN

Ailing WEI

Huijuan LIU

Related Institution

Henan University of Chinese Medicine

Guangxi University of Chinese Medicine

The First Affiliated Hospital of Henan University of Chinese Medicine

Guangzhou University of Chinese Medicine

Henan Academy of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰